SK282495B6 - Acylovaný inzulínový derivát a farmaceutický prostriedok, ktorý ho obsahuje - Google Patents

Acylovaný inzulínový derivát a farmaceutický prostriedok, ktorý ho obsahuje Download PDF

Info

Publication number
SK282495B6
SK282495B6 SK324-96A SK32496A SK282495B6 SK 282495 B6 SK282495 B6 SK 282495B6 SK 32496 A SK32496 A SK 32496A SK 282495 B6 SK282495 B6 SK 282495B6
Authority
SK
Slovakia
Prior art keywords
human insulin
insulin
glu
ala
gly
Prior art date
Application number
SK324-96A
Other languages
English (en)
Slovak (sk)
Other versions
SK32496A3 (en
Inventor
Svend Havelund
John Broberg Halstrom
Ib Jonassen
Asser Sloth Andersen
Jan Markussen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK282495(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK104493A external-priority patent/DK104493D0/da
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of SK32496A3 publication Critical patent/SK32496A3/sk
Publication of SK282495B6 publication Critical patent/SK282495B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK324-96A 1993-09-17 1994-09-16 Acylovaný inzulínový derivát a farmaceutický prostriedok, ktorý ho obsahuje SK282495B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK104493A DK104493D0 (da) 1993-09-17 1993-09-17 Hidtil ukendte peptider
US19082994A 1994-02-02 1994-02-02
PCT/DK1994/000347 WO1995007931A1 (fr) 1993-09-17 1994-09-16 Insuline acylee

Publications (2)

Publication Number Publication Date
SK32496A3 SK32496A3 (en) 1996-11-06
SK282495B6 true SK282495B6 (sk) 2002-02-05

Family

ID=26065125

Family Applications (1)

Application Number Title Priority Date Filing Date
SK324-96A SK282495B6 (sk) 1993-09-17 1994-09-16 Acylovaný inzulínový derivát a farmaceutický prostriedok, ktorý ho obsahuje

Country Status (30)

Country Link
US (1) US5750497A (fr)
EP (2) EP0792290B1 (fr)
JP (3) JP3014764B2 (fr)
KR (1) KR100310122B1 (fr)
CN (1) CN1056618C (fr)
AT (1) ATE204882T1 (fr)
AU (2) AU682061B2 (fr)
BG (1) BG61611B1 (fr)
BR (1) BR9407508A (fr)
CA (1) CA2171424C (fr)
CZ (1) CZ287945B6 (fr)
DE (2) DE69428134T2 (fr)
DK (1) DK0792290T3 (fr)
ES (1) ES2163451T3 (fr)
FI (1) FI117055B (fr)
FR (1) FR04C0020I2 (fr)
HU (1) HU217684B (fr)
IL (1) IL110977A (fr)
LU (1) LU91101I2 (fr)
NL (1) NL300160I2 (fr)
NO (3) NO316944B1 (fr)
NZ (1) NZ273285A (fr)
PL (1) PL178466B1 (fr)
PT (1) PT792290E (fr)
RO (1) RO112873B1 (fr)
RU (1) RU2164520C2 (fr)
SI (1) SI0792290T1 (fr)
SK (1) SK282495B6 (fr)
UA (1) UA45321C2 (fr)
WO (1) WO1995007931A1 (fr)

Families Citing this family (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
DE4437604A1 (de) * 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
CZ289343B6 (cs) * 1995-03-17 2002-01-16 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek pro léčení diabetes
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US20010041786A1 (en) * 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
GB9513967D0 (en) * 1995-07-08 1995-09-06 Univ Leicester Insulin
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
AU720484B2 (en) * 1996-06-20 2000-06-01 Novo Nordisk A/S Insulin preparations containing NaCl
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
EP0938502B1 (fr) * 1996-07-11 2004-10-06 Novo Nordisk A/S Procede selectif d'alcylation
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
EP1627642A3 (fr) * 1997-03-20 2006-04-19 Novo Nordisk A/S Cristaux d'insuline depourvus de zinc et utiles dans des compositions pour les voies respiratoires
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989644B (en) * 1997-10-24 2000-04-25 Lilly Co Eli Insoluble insulen compositions.
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
PE123799A1 (es) * 1997-10-24 1999-12-13 Lilly Co Eli Composiciones insolubles de insulina
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
EP1396272A1 (fr) * 1997-12-23 2004-03-10 Eli Lilly & Company Compositions insolubles d'insuline pour le contrôle du glucose sanguin
JP2002500196A (ja) * 1998-01-09 2002-01-08 ノヴォ ノルディスク アクティーゼルスカブ 安定化させたインスリン組成物
AU2712899A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
JP2002518408A (ja) * 1998-06-12 2002-06-25 キングス・カレツジ・ロンドン インスリン類似体
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
WO2001072323A2 (fr) 2000-03-24 2001-10-04 Genentech, Inc. Utilisation de l'insuline pour traiter des affections des cartilages
WO2001085256A2 (fr) * 2000-05-05 2001-11-15 Novo Nordisk A/S Maladie neurophatique grave
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
CA2415425A1 (fr) * 2000-07-10 2002-01-17 Btg International Limited Derives d'insuline et synthese desdits derives
CN1406131A (zh) * 2000-12-25 2003-03-26 株式会社资生堂 活化交感神经的香料组合物
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
EP1698636A1 (fr) * 2001-05-02 2006-09-06 Novo Nordisk A/S Procédé de préparation de conjagates de peptides avec des acides biliaire
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
MXPA04001560A (es) 2001-08-28 2004-05-17 Lilly Co Eli Premezclas de glp-1 e insulina basal.
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
ATE446971T1 (de) 2001-09-07 2009-11-15 Biocon Ltd Verfahren zur synthese von insulinpolypeptid- oligomer-konjugaten und proinsulinpolypeptid- oligomer-konjugaten und verfahren zu deren synthese
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
WO2003031432A1 (fr) 2001-10-12 2003-04-17 Novo Nordisk A/S Nouvelles piperidines substituees
CA2463803A1 (fr) 2001-10-19 2003-05-01 Eli Lilly And Company Melanges biphasiques de glp-1 et d'insuline
BR0213583A (pt) 2001-11-19 2004-08-24 Novo Nordisk As Processo para preparar um composto de insulina, e, composto de insulina
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
JP5599543B2 (ja) * 2002-05-07 2014-10-01 ノヴォ ノルディスク アー／エス 単量体インスリン及びアシル化インスリンを含む可溶性製剤
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
KR101131783B1 (ko) * 2002-09-25 2012-03-30 노보 노르디스크 에이/에스 아실화된 펩타이드의 제조방법
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
WO2004085472A1 (fr) * 2003-03-27 2004-10-07 Novo Nordisk A/S Procede de fabrication de precurseurs de l'insuline humaine et insuline humaine
ATE482747T1 (de) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
WO2004096266A1 (fr) * 2003-05-02 2004-11-11 Novo Nordisk A/S Stabilite physique amelioree de preparations d'insuline
PL1641616T3 (pl) 2003-06-27 2011-09-30 Novo Nordisk As Wysoce wilgocioszczelny pojemnik dla medycznych mieszanin ciekłych
ES2472421T3 (es) 2003-08-05 2014-07-01 Novo Nordisk A/S Nuevos derivados de insulina
EP2264065B1 (fr) 2003-08-05 2017-03-08 Novo Nordisk A/S Nouveaux derives de l'insuline
EP1687428A1 (fr) 2003-11-14 2006-08-09 Novo Nordisk A/S Procede de fabrication d'insuline acylee
CN102784386A (zh) 2003-11-20 2012-11-21 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
ATE517119T1 (de) 2003-12-03 2011-08-15 Novo Nordisk As Einzelketteninsulin
CN1898087A (zh) 2003-12-22 2007-01-17 诺沃挪第克公司 用于储存药物液体的透明、柔性、不可渗透的塑料容器
CA2552043A1 (fr) 2004-01-21 2005-08-04 Novo Nordisk A/S Conjugaison de peptides induite par la transglutaminase
AU2005222613B2 (en) * 2004-03-12 2009-12-17 Biodel, Inc. Rapid acting drug delivery compositions
WO2006008238A1 (fr) * 2004-07-16 2006-01-26 Novo Nordisk A/S Procede d'acylation selective
UA103758C2 (ru) 2004-07-19 2013-11-25 Биокон Лимитед Конъюгаты олигомеров инсулина, их композиции и применение
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006082205A1 (fr) * 2005-02-02 2006-08-10 Novo Nordisk A/S Dérivés d'insuline
ES2438145T3 (es) 2005-02-02 2014-01-16 Novo Nordisk A/S Nuevos derivados de insulina
US20090060861A1 (en) * 2005-05-25 2009-03-05 Novo Nordisk A/S Stabilized Polypeptide Formulations
CN101180081B (zh) 2005-05-25 2015-08-26 诺沃-诺迪斯克有限公司 稳定的多肽制剂
EP1888104A2 (fr) * 2005-05-26 2008-02-20 Novo Nordisk A/S Insuline acylee tres pure
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
EP1910317B1 (fr) 2005-07-20 2013-07-03 Eli Lilly And Company Composés joints en position 1-amino
WO2007020256A1 (fr) 2005-08-16 2007-02-22 Novo Nordisk A/S Procede permettant de realiser des polypeptides d'insuline matures
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2007123581A1 (fr) 2005-11-17 2007-11-01 Eli Lilly And Company Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
WO2007084460A2 (fr) 2006-01-18 2007-07-26 Qps, Llc Compositions pharmaceutiques a stabilite amelioree
ATE557037T1 (de) 2006-02-27 2012-05-15 Novo Nordisk As Insulin derivate
EP1996223A1 (fr) * 2006-03-13 2008-12-03 Novo Nordisk A/S Insuline monocaténaire acylée
WO2007104786A1 (fr) 2006-03-15 2007-09-20 Novo Nordisk A/S Melanges d'amyline et d'insuline
NZ570524A (en) 2006-03-28 2011-08-26 High Point Pharmaceuticals Llc Benzothiazoles having histamine H3 receptor activity
ES2378574T3 (es) 2006-04-24 2012-04-16 Eli Lilly & Company Pirrolidinonas ciclohexilo substituidas como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
ES2548393T3 (es) 2006-05-09 2015-10-16 Novo Nordisk A/S Derivado de insulina
ES2553154T3 (es) 2006-05-09 2015-12-04 Novo Nordisk A/S Derivado de la insulina
US7714025B2 (en) * 2006-05-10 2010-05-11 Arizona Biomedical Research Commission Modified chalcone compounds as antimitotic agents
CN101460487A (zh) 2006-05-29 2009-06-17 高点制药有限责任公司 3-(1，3-苯并间二氧杂环戊烯- 5-基)-6-(4-环丙基哌嗪-1-基)-哒嗪、其盐和溶剂合物及其作为组胺h3受体拮抗剂的用途
WO2008008363A1 (fr) 2006-07-11 2008-01-17 Qps, Llc Compositions pharmaceutiques pour délivrance à libération prolongée de peptides
JP5550338B2 (ja) 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
WO2008037735A1 (fr) 2006-09-27 2008-04-03 Novo Nordisk A/S Procédé de fabrication de polypeptides d'insuline mature
WO2008049711A1 (fr) * 2006-10-27 2008-05-02 Novo Nordisk A/S Insuline à peptide ajouté
ES2563038T3 (es) 2007-04-30 2016-03-10 Novo Nordisk A/S Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
JP5675347B2 (ja) 2007-06-01 2015-02-25 ノボ・ノルデイスク・エー／エス 安定した非水性薬学的組成物
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
EP2178909B1 (fr) 2007-08-13 2015-10-21 Novo Nordisk A/S Analogues de l'insuline à action rapide
BRPI0818004B8 (pt) * 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
EP2058330A1 (fr) * 2007-11-08 2009-05-13 Novo Nordisk A/S Dérivé d'insuline
ES2543393T3 (es) 2007-11-08 2015-08-18 Novo Nordisk A/S Derivado de insulina
PL2209800T3 (pl) 2007-11-16 2013-12-31 Novo Nordisk As Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
AU2009204309B2 (en) * 2008-01-04 2012-11-22 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
EP2910571B1 (fr) 2008-03-18 2016-10-05 Novo Nordisk A/S Analogues de l'insuline acylés, stabilisés à la protéase
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
BRPI0823004B8 (pt) 2008-08-07 2021-05-25 Biocon Ltd processo para preparação de compostos de insulina
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
CN102223797A (zh) 2008-11-21 2011-10-19 高点制药有限责任公司 金刚烷基苯甲酰胺化合物
WO2010088286A1 (fr) 2009-01-28 2010-08-05 Smartcells, Inc. Conjugués synthétiques et leurs utilisations
MA33064B1 (fr) * 2009-01-28 2012-02-01 Smartcells Inc Systemes à base de conjugués pour administration contrôlée de médicaments
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
WO2010107519A1 (fr) 2009-03-20 2010-09-23 Smartcells, Inc. Conjugués fonctionnalisés aux extrémités et leurs utilisations
EP2437786B1 (fr) 2009-06-01 2016-05-18 Yeda Research and Development Co. Ltd. Promédicaments contenant une sonde se liant à l'albumine
WO2011064316A2 (fr) 2009-11-25 2011-06-03 Paolo Botti Administration de peptides par voie muqueuse
EP2359843A1 (fr) 2010-01-21 2011-08-24 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
TW201141513A (en) 2010-04-14 2011-12-01 Sanofi Aventis Insulin-siRNA conjugates
AU2011252127B2 (en) * 2010-05-10 2014-02-20 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
EP2627670A2 (fr) * 2010-10-15 2013-08-21 Novo Nordisk A/S Nouveaux dérivés d'insuline à extrémité n modifiée
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
KR102025442B1 (ko) 2010-12-22 2019-09-25 박스알타 인코퍼레이티드 단백질에 수용성 지방산 유도체를 접합하기 위한 물질 및 방법
AU2012208349A1 (en) 2011-01-20 2013-07-18 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
US9480751B2 (en) 2011-04-11 2016-11-01 Yeda Research And Development Co. Ltd. Albumin binding probes and drug conjugates thereof
EP2548570A1 (fr) 2011-07-19 2013-01-23 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
WO2013086927A1 (fr) * 2011-12-15 2013-06-20 上海恒瑞医药有限公司 Analogue d'insuline humaine et son dérivé acylé
CA2870313A1 (fr) 2012-04-11 2013-10-17 Novo Nordisk A/S Formulations a base d'insuline
WO2013164375A1 (fr) 2012-05-01 2013-11-07 Novo Nordisk A/S Composition pharmaceutique
EP2925345B1 (fr) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Méthode de préparation d'insuline et d'analogues d'insuline à base du peptide de la partie terminale carboxy (ctp) o-glycosylé
EP2991672A1 (fr) 2013-04-30 2016-03-09 Novo Nordisk A/S Schéma d'administration d'un nouveau type
ES2927607T3 (es) 2013-09-13 2022-11-08 Scripps Research Inst Agentes terapéuticos modificados y composiciones de los mismos
WO2015052088A1 (fr) * 2013-10-07 2015-04-16 Novo Nordisk A/S Nouveau dérivé d'un analogue de l'insuline
EP4212180A1 (fr) 2013-12-18 2023-07-19 The Scripps Research Institute Agents thérapeutiques modifiés, conjugués lipidiques peptidiques agrafés et compositions associées
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
WO2015196174A1 (fr) 2014-06-20 2015-12-23 Greene Howard E Dispositifs et procédés d'administration de perfusion
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
JP2018531900A (ja) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
EP3495384A4 (fr) * 2016-08-02 2020-02-26 Jiangsu Hengrui Medicine Co., Ltd. Dérivé acylé de l'insuline humaine ou son analogue
EP3329930A1 (fr) 2016-12-05 2018-06-06 Nuritas Limited Compositions pharmaceutiques
ES2932498T3 (es) 2016-12-05 2023-01-20 Nuritas Ltd Composiciones que comprenden el péptido WKDEAGKPLVK
MX2019006463A (es) 2016-12-16 2019-08-14 Novo Nordisk As Composiciones farmaceuticas que contienen insulina.
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
KR20190038456A (ko) * 2017-09-29 2019-04-08 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
WO2019125879A2 (fr) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Systèmes à base de conjugués pour l'administration contrôlée d'insuline
EP3727424A4 (fr) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. Systèmes à base de conjugués pour l'administration contrôlée d'insuline
EP3750998A4 (fr) 2018-02-09 2022-02-23 Jiangsu Hengrui Medicine Co., Ltd. Gène précurseur à codon optimisé et gène de peptide signal de l'analogue de l'insuline humaine
EP3805257A4 (fr) 2018-05-24 2022-03-16 Jiangsu Hengrui Medicine Co., Ltd. Procédé de préparation d'un précurseur d'insuline humaine recombinée ou d'un analogue associé
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
CA3122637A1 (fr) 2018-12-11 2020-06-18 Sanofi Liant peptidique
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
CN111909255A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 胰岛素衍生物及其制备方法
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
BR112022009510A2 (pt) 2019-12-11 2022-08-16 Novo Nordisk As Análogo de insulina, composição farmacêutica, e, método de tratamento, prevenção ou alívio de uma doença ou distúrbio ou condição
JP2023510218A (ja) 2019-12-30 2023-03-13 ガン アンド リー ファーマスゥーティカルズ カンパニー リミテッド 長時間作用型ｇｌｐ－１化合物
CN118420744A (zh) 2019-12-30 2024-08-02 甘李药业股份有限公司 胰岛素衍生物
US20230082544A1 (en) 2020-02-18 2023-03-16 Novo Nordisk A/S Pharmaceutical formulations
AU2021247169A1 (en) 2020-03-31 2022-10-20 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
CA3198757A1 (fr) 2020-11-19 2022-05-27 Protomer Technologies Inc. Composes aromatiques contenant du bore et analogues d'insuline
EP4299057A1 (fr) 2022-06-30 2024-01-03 Adocia Compositions solides comportant un peptide ou une protéine et un acide aminé acylé
EP4180060A1 (fr) 2021-11-15 2023-05-17 Adocia Compositions solides comportant un peptide ou une protéine et un acide aminé acylé
WO2023084118A1 (fr) 2021-11-15 2023-05-19 Adocia Compositions solides comprenant un peptide ou une protéine et un acide aminé acylé
CN118574842A (zh) 2022-01-28 2024-08-30 甘李药业股份有限公司 酰化胰岛素
EP4299071A1 (fr) 2022-07-01 2024-01-03 Adocia Compositions comprenant un peptide ou une protéine et un acide aminé acylé
WO2024051787A1 (fr) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 Dérivé d'insuline acylé à action prolongée et son utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3823125A (en) * 1969-10-14 1974-07-09 American Home Prod N-aminoacyl-substituted insulins
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) * 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
DK319780A (da) * 1980-07-24 1982-01-25 Forenede Bryggerier As Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
JPH01254699A (ja) * 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
AU8091091A (en) * 1990-07-26 1992-02-18 University Of Iowa Research Foundation, The Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
US5336782A (en) * 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester

Also Published As

Publication number Publication date
EP0792290A1 (fr) 1997-09-03
EP0792290B1 (fr) 2001-08-29
DE122004000035I2 (de) 2009-08-06
EP1132404A3 (fr) 2002-03-27
NL300160I2 (nl) 2005-07-01
NO2017041I1 (no) 2017-08-01
IL110977A (en) 2000-06-29
WO1995007931A1 (fr) 1995-03-23
CN1056618C (zh) 2000-09-20
CZ287945B6 (cs) 2001-03-14
CZ78996A3 (en) 1996-10-16
AU7652094A (en) 1995-04-03
JPH09502867A (ja) 1997-03-25
NO961070D0 (no) 1996-03-15
EP1132404A2 (fr) 2001-09-12
RU2164520C2 (ru) 2001-03-27
BG61611B1 (bg) 1998-01-30
DK0792290T3 (da) 2001-10-01
SI0792290T1 (en) 2001-12-31
FI961220A0 (fi) 1996-03-15
NO2004006I1 (no) 2004-10-11
JP2002308899A (ja) 2002-10-23
CN1133598A (zh) 1996-10-16
KR960704925A (ko) 1996-10-09
HU217684B (hu) 2000-03-28
NZ273285A (en) 1997-10-24
JP2000060556A (ja) 2000-02-29
JP3917333B2 (ja) 2007-05-23
AU4846197A (en) 1998-02-19
CA2171424C (fr) 2002-06-04
DE69428134D1 (de) 2001-10-04
PT792290E (pt) 2002-01-30
AU682061B2 (en) 1997-09-18
KR100310122B1 (ko) 2002-04-24
NO2004006I2 (fr) 2008-02-04
DE69428134T2 (de) 2002-05-02
BG100420A (bg) 1996-12-31
JP3014764B2 (ja) 2000-02-28
ES2163451T3 (es) 2002-02-01
RO112873B1 (ro) 1998-01-30
HU9600676D0 (en) 1996-05-28
JP4060583B2 (ja) 2008-03-12
DE122004000035I1 (de) 2005-02-24
NO2017041I2 (no) 2018-11-19
HUT75991A (en) 1997-05-28
FR04C0020I2 (fr) 2005-05-27
CA2171424A1 (fr) 1995-03-23
SK32496A3 (en) 1996-11-06
ATE204882T1 (de) 2001-09-15
LU91101I2 (en) 2004-11-08
PL313444A1 (en) 1996-07-08
US5750497A (en) 1998-05-12
BR9407508A (pt) 1997-01-07
IL110977A0 (en) 1994-11-28
UA45321C2 (uk) 2002-04-15
NL300160I1 (nl) 2004-12-01
FI961220A (fi) 1996-05-14
NO316944B1 (no) 2004-07-05
NO961070L (no) 1996-05-15
PL178466B1 (pl) 2000-05-31
FI117055B (fi) 2006-05-31
FR04C0020I1 (fr) 2004-10-29

Similar Documents

Publication Publication Date Title
SK282495B6 (sk) Acylovaný inzulínový derivát a farmaceutický prostriedok, ktorý ho obsahuje
US6869930B1 (en) Acylated insulin
US6011007A (en) Acylated insulin
AU2004261353B2 (en) Novel insulin derivatives
EP1991576A1 (fr) Dérivés d'insuline
EP2287184A2 (fr) Nouveaux dérivés d'insuline
AU745983B2 (en) Acylated insulin

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20140916

SPCF Filing of an spc

Free format text: PRODUCT NAME: NEB29-TETRADEKANOYL-DES(B30) HUMANNY INZULIN; NAT. REGISTRATION: EU/1/04/278/001, EU/1/04/278/002, EU/1/04/278/003, EU/1/04/278/004, EU/1/04/278/005, EU/1/04/278/006, EU/1/04/278/007, EU/1/04/278/008, EU/1/04/278/009, 20040601; FIRST REGISTRATION: CH 56370, 56371, 56372, 20031110

Spc suppl protection certif: 5001-2004

Filing date: 20151113

SPCZ Extension of validity of an spc

Free format text: PRODUCT NAME: NEPSILONB29-TETRADEKANOYL-DES(B30) HUMANNY; NAT. REGISTRATION NO/DATE: EU/1/04/278/001 - EU/1/04/278/009 20040601; FIRST REGISTRATION: CH 56370 - 56372 20031110

Spc suppl protection certif: 21 5001-2004

Filing date: 20151113

Extension date: 20190510